Showing 6451-6460 of 10817 results for "".
- Study Aims to Define Photosensitivity Diagnosis in Atopic Dermatitishttps://practicaldermatology.com/news/study-aims-define-photosensitivity-diagnosis-atopic-dermatitis/2467967/A new study aims to refine diagnostic criteria for photosensitivity in patients with atopic dermatitis (AD). “Previous reports have characterized photosensitivity in AD, but with differences in terminology and criteria,” the authors noted, suggesting a need for better guidance. The
- Dupilumab Reduces Inflammatory Biomarkers in Pediatric AD: Studyhttps://practicaldermatology.com/news/dupilumab-reduces-inflammatory-biomarkers-pediatric-ad/2467953/Dupilumab significantly reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis (AD), according to results from recent phase 3 trials. Pediatric patients treated with dupilumab demonstrated substantial reductions in key serum biomarkers associated w
- European Commission Approves Celltrion’s Stelara Biosimilar SteQeymahttps://practicaldermatology.com/news/european-commission-approves-celltrions-stelara-biosimilar-steqeyma/2467952/Celltrion announced that the European Commission (EC) has approved SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases, including psoriasis. The EC's approval follows a positive opinion from the Committee for Medici
- Review: No Safety Concerns for Live Vaccines with Dupilumabhttps://practicaldermatology.com/news/systematic-review-no-safety-concerns-live-vaccines-dupilumab/2467944/Live vaccines are likely safe and effective for patients undergoing dupilumab treatment, according to results from a systematic review and expert consensus. Authors for a new systematic review, combined with expert input from a Delphi panel, provided insights into the safety and efficacy o
- Timber Pharmaceuticals Fails Phase 3 Trial for Congenital Ichthyosis Drug Candidatehttps://practicaldermatology.com/news/timber-pharmaceuticals-fails-phase-3-trial-congenital-ichthyosis-drug-candidate/2467911/LEO Pharma's subsidiary, Timber Pharmaceuticals, failed a late-stage trial for its investigational topical ointment formulation of isotretinoin for treating moderate to severe congenital ichthyosis. The phase 3 ASCEND trial was 12-week randomized, double-blind clinical study evaluating TM
- Quitting Smoking Reduces Hidradenitis Suppurativa Riskhttps://practicaldermatology.com/news/quitting-smoking-reduces-hidradenitis-suppurativa-risk/2467901/A new study suggests that smoking cessation is associated with reduced risk of developing hidradenitis suppurativa (HS). Researchers for the population-based cohort study looked at the relationship between the change in smoking habits and the incidence of HS in more than 6 million partic
- Genome-Wide Study Reveals Genetic Correlation Between Melanoma Subtypeshttps://practicaldermatology.com/news/genome-wide-study-reveals-genetic-correlation-between-melanoma-subtypes/2467851/Data from a recent genome-wide association study (GWAS) looking at the genetic underpinnings of in situ and invasive melanoma show significant shared genetic architecture between the two. Researchers for the study used data from four population-based genetic cohorts, including the UK Bio
- Five-Year Study Validates Dupilumab for Atopic Dermatitis Managementhttps://practicaldermatology.com/news/five-year-study-validates-dupilumab-atopic-dermatitis-management/2467714/New research has provided evidence of benefit from a long-term strategy of dupilumab for the treatment of atopic dermatitis (AD). Researchers for the multicenter cohort study looked at clinical effectiveness, response times, and reasons for discontinuation of dupilumab treatment over a pe
- Galderma to Pursue a Scientific Partnership with L’Oréalhttps://practicaldermatology.com/news/galderma-to-pursue-a-scientific-partnership-with-loreal/2467670/Galderma has signed a memorandum of understanding with L’Oréal to work toward a new research and development (R&D) collaboration in the form of a scientific partnership, according to a company news release. The partnership would
- Nemolizumab Meets Key Endpoints in ARCADIA Studieshttps://practicaldermatology.com/news/nemolizumab-meets-key-endpoints-arcadia-studies/2467533/Nemolizumab, a monoclonal antibody targeting the IL-31 receptor, showed efficacy for the treatment of atopic dermatitis, particularly pruritus and sleep disturbance, according to an announcement from Galderma. The full results of the phase III ARCADIA 1 and 2 trials for nemolizumab were pu